Back to results
US 2022/0088129 A1Published application
Long-acting vegf inhibitors for intraocular neovascularization
AssigneeThe Regents of the University of California
InventorNapoleone FERRARA
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treating a VEGF-related ophthalmic disorder in a subject in need comprising, administering intravitreally to the subject a therapeutically effective amount of an anti-VEGF agent, comprising a VEGF binding portion operatively linked to a Fc-IgG, wherein the VEGF binding portion comprises at least one VEGF binding domain that is an IgG-like domain 2 of VEGFR-1.
Claims15
A purified anti-VEGF agent having formula N-D2-D3-Fc:
- wherein N is an N-terminal peptide comprising amino acids 27-34 of SEQ ID NO:
- 3,
- wherein D2 is an IgG-like domain 2 of VEGFR-1,
- wherein D3 is an IgG-like domain 3 of VEGFR-1, and
- wherein Fc is the Fc domain of a human IgG immunoglobulin.
2 more elements
Dependencies are inferred from the claim text.